(Q34123846)

31 July 2017

1 reference

title

Studies of minimal residual disease in acute lymphocytic leukemia (English)

1 reference

31 July 2017

0 references

1 reference

Stock W

1

1 reference

PubMed ID

11147224

31 July 2017

Estrov Z

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

Hematology / Oncology Clinics of North America

31 July 2017

1 reference

31 July 2017

14

1 reference

31 July 2017

6

1 reference

31 July 2017

1289-305, viii-ix

1 reference

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Detection of residual disease in acute lymphoblastic leukemia of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Silence of the leukemic clone.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Real time quantitative PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Modern molecular diagnostics and the management of haematological malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970187-8

7 January 2021

10.1016/S0889-8588(05)70187-8

Identifiers

DOI

1 reference

release_h2pnconmmrdadjnrcfaq6o6pt4

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h2pnconmmrdadjnrcfaq6o6pt4

24 November 2022

mapped directly with Wikidata item

PubMed ID

11147224

1 reference

PubMed ID

11147224